EOS100850

iTeos Therapeutics · Phase 1 active Small molecule

At a glance

Generic name	EOS100850
Also known as	Inupadenant
Sponsor	iTeos Therapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EOS100850 CI brief — competitive landscape report
EOS100850 updates RSS · CI watch RSS
iTeos Therapeutics portfolio CI